We have located links that may give you full text access.
Pretreatment with a Novel Toll-like Receptor 4 Agonist Phosphorylated Hexaacyl Disaccharide Attenuates Renal Ischemia-Reperfusion Injury.
American Journal of Physiology. Renal Physiology 2023 March 31
OBJECTIVE: Acute kidney injury is common in surgical and critically ill patients. This study examined if pretreatment with a TLR4 agonist attenuated ischemia reperfusion-induced AKI (IRI-AKI).
DESIGN: A blinded, randomized controlled study in mice pretreated with PHAD, a synthetic TLR4 agonist. Two cohorts of male BALB/c mice received intraperitoneal vehicle or PHAD (10, 20, or 40 µg); or intravenous vehicle or PHAD (2, 20, or 200 µg) at 48 and 24 hours prior to unilateral renal pedicle clamping and simultaneous contralateral nephrectomy. A separate cohort of mice received vehicle or 200 µg of PHAD followed by bilateral IRI-AKI. Mice were monitored for 3 days post-reperfusion and euthanized for analysis.
METHODS AND RESULTS: Kidney function was assessed by BUN and serum creatinine measurements. Kidney tubular injury was assessed by semi-quantitative analysis of tubular morphology on PAS-stained kidney sections, and kidney mRNA quantification of injury (N-Gal, Kim-1 and HO-1) and inflammation (IL-6, IL-1b and TNF-α) using qRT-PCR technique. Immunohistochemistry was used to quantify Kim-1 and F4/80 protein to assess kidney injury and macrophages, respectively. PHAD pretreatment yielded dose-dependent kidney function preservation during unilateral IRI-AKI. Histological injury and N-Gal mRNA were lower, and IL-1b mRNA was higher in 200 µg 3D 6-Acyl PHAD treated mice. Similar pretreatment protection was noted at 200 mg PHAD after bilateral IRI-AKI, with significantly reduced Kim-1 immunostaining in the outer medulla of mice treated with PHAD after bilateral IRI-AKI.
CONCLUSIONS: PHAD pretreatment leads to dose-dependent protection from renal injury after unilateral and bilateral IRI-AKI in mice.
DESIGN: A blinded, randomized controlled study in mice pretreated with PHAD, a synthetic TLR4 agonist. Two cohorts of male BALB/c mice received intraperitoneal vehicle or PHAD (10, 20, or 40 µg); or intravenous vehicle or PHAD (2, 20, or 200 µg) at 48 and 24 hours prior to unilateral renal pedicle clamping and simultaneous contralateral nephrectomy. A separate cohort of mice received vehicle or 200 µg of PHAD followed by bilateral IRI-AKI. Mice were monitored for 3 days post-reperfusion and euthanized for analysis.
METHODS AND RESULTS: Kidney function was assessed by BUN and serum creatinine measurements. Kidney tubular injury was assessed by semi-quantitative analysis of tubular morphology on PAS-stained kidney sections, and kidney mRNA quantification of injury (N-Gal, Kim-1 and HO-1) and inflammation (IL-6, IL-1b and TNF-α) using qRT-PCR technique. Immunohistochemistry was used to quantify Kim-1 and F4/80 protein to assess kidney injury and macrophages, respectively. PHAD pretreatment yielded dose-dependent kidney function preservation during unilateral IRI-AKI. Histological injury and N-Gal mRNA were lower, and IL-1b mRNA was higher in 200 µg 3D 6-Acyl PHAD treated mice. Similar pretreatment protection was noted at 200 mg PHAD after bilateral IRI-AKI, with significantly reduced Kim-1 immunostaining in the outer medulla of mice treated with PHAD after bilateral IRI-AKI.
CONCLUSIONS: PHAD pretreatment leads to dose-dependent protection from renal injury after unilateral and bilateral IRI-AKI in mice.
Full text links
Related Resources
Trending Papers
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International Journal of Molecular Sciences 2024 May 2
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app